Parkwoods Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Parkwoods Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$524K	Buy	9,531 +850	+10%	+$34.8K	0.08%	98
2026 Q1	$288K	Buy	8,681 +1,673	+24%	+$49.9K	0.07%	86
2025 Q4	$209K	Buy	7,008 +7	+0.1%	+$229	0.06%	102
2025 Q3	$253K	Hold	7,001	–	–	0.09%	84
2025 Q2	$252K	Hold	7,001	–	–	0.15%	61
2025 Q1	$276K	Hold	7,001	–	–	0.19%	37
2024 Q4	$211K	Buy	+7,001	New	+$201K	0.17%	29

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Parkwoods Wealth Partners's TGTX Position: Q2 2026 in Review

Parkwoods Wealth Partners increased its TG Therapeutics (TGTX) stake by 9.8% in Q2 2026, buying an estimated $34.8K and bringing the position to 9,531 shares worth $524K. The position accounts for 0.08% of the portfolio, ranked #98.

Parkwoods Wealth Partners first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Parkwoods Wealth Partners held 9,531 shares of TG Therapeutics worth $524K as of Q2 2026.
Parkwoods Wealth Partners bought 850 TG Therapeutics shares in Q2 2026, an estimated $34.8K.
TG Therapeutics made up 0.08% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #98 holding.
Parkwoods Wealth Partners first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.